Effect of neoadjuvant chemotherapy on breast cancer phenotype, ER/PR and HER2 expression – Implications for the practising oncologist
- 1 June 2016
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 60, 40-48
Abstract
No abstract availableKeywords
Funding Information
- Leeds CR-UK (482442)
This publication has 27 references indexed in Scilit:
- Reliability of core needle biopsy for determining ER and HER2 status in breast cancerAnnals of Oncology, 2012
- The manufacture and assessment of tissue microarrays: suggestions and criteria for analysis, with breast cancer as an exampleJournal of Clinical Pathology, 2012
- A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differencesBreast Cancer Research and Treatment, 2011
- HER2 testing in the UK: recommendations for breast and gastric in-situ hybridisation methodsJournal of Clinical Pathology, 2011
- Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival OutcomesClinical Cancer Research, 2009
- Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancerBritish Journal of Cancer, 2009
- The Effect of Neoadjuvant Chemotherapy on Histologic Grade, Hormone Receptor Status, and Her2/neu Status in Breast CarcinomaThe Breast Journal, 2008
- Changes in and Prognostic Value of Hormone Receptor Status in a Series of Operable Breast Cancer Patients Treated with Neoadjuvant ChemotherapyThe Oncologist, 2007
- Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapy.Endocrine-Related Cancer, 2003
- HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic processCancer, 2002